 |
HERLEV, Denmark, May 8, 2025 /PRNewswire/ -- Nordic Bioscience announces that its PRO-C3 test is launched by Roche Diagnostics on their cobas analysers. The Roche Elecsys® PRO-C3, used with the ADAPT formula (age, diabetes status, PRO-C3, platelets), assesses liver fibrosis severity – a disease responsible for approximately one in every 25 deaths worldwide.
The nordicPRO-C3â„¢ biomarker is already validated in Nordic Bioscience CAP-CLIA certified laboratory in Denmark. This demonstrates that Nordic Bioscience is dedicated to helping patients in a precision medicine driven approach, and our Platform provides the quality needed for regulatory approval.
Nordic Bioscience's scientists have over that last 10 years published more than 250 scientific papers on PRO-C3 making us the leading place for research within PRO-C3 and fibrotic related diseases.
PRO-C3 is the first of the Nordic Bioscience-biomarkers from our fibrosis panel which has been CE-approved. 40% of deaths in the western world are associated with alterations of organs such as the liver, and we provide the tools to quantify this. These are the tools of modern clinical chemistry.
"The Elecsys PRO-C3 test is the first test launched from the collaboration between Nordic Bioscience and Roche Diagnostics. We are proud that our technology becomes globally available to make a difference for patients." said Morten Karsdal, CEO of Nordic Bioscience.
About PRO-C3
PRO-C3 was invented by Nordic Bioscience and has up until now been available as a service performed in Nordic Bioscience's laboratory in Denmark using the nordicPRO-C3â„¢ test. The Elecsys PRO-C3 test is developed under a license agreement between Nordic Bioscience and Roche Diagnostics. For more information including scientific information on PRO-C3 see https://www.nordicbioscience.com/technology/biomarkers/pro-c3-nordicpro-c3
About Nordic Bioscience
Nordic Bioscience is a Danish biomarker company headquartered in Herlev, Denmark. We are engaged in biomarker development using our unique neoepitope technology. We combine our expertise in biomarker development with preclinical and clinical research. This enables us to develop biomarkers that provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting. For more information about Nordic Bioscience, visit us at https://www.nordicbioscience.com
For product related inquires please use https://www.nordicbioscience.com/contact
HERLEV, Denmark, May 8, 2025 /PRNewswire/ -- Nordic Bioscience announces that its PRO-C3 test is launched by Roche Diagnostics on their cobas analysers. The Roche Elecsys® PRO-C3, used with the ADAPT formula (age, diabetes status, PRO-C3, platelets), assesses liver fibrosis severity – a disease responsible for approximately one in every 25 deaths worldwide.
The nordicPRO-C3â„¢ biomarker is already validated in Nordic Bioscience CAP-CLIA certified laboratory in Denmark. This demonstrates that Nordic Bioscience is dedicated to helping patients in a precision medicine driven approach, and our Platform provides the quality needed for regulatory approval.
Nordic Bioscience's scientists have over that last 10 years published more than 250 scientific papers on PRO-C3 making us the leading place for research within PRO-C3 and fibrotic related diseases.
PRO-C3 is the first of the Nordic Bioscience-biomarkers from our fibrosis panel which has been CE-approved. 40% of deaths in the western world are associated with alterations of organs such as the liver, and we provide the tools to quantify this. These are the tools of modern clinical chemistry.
"The Elecsys PRO-C3 test is the first test launched from the collaboration between Nordic Bioscience and Roche Diagnostics. We are proud that our technology becomes globally available to make a difference for patients." said Morten Karsdal, CEO of Nordic Bioscience.
About PRO-C3
PRO-C3 was invented by Nordic Bioscience and has up until now been available as a service performed in Nordic Bioscience's laboratory in Denmark using the nordicPRO-C3â„¢ test. The Elecsys PRO-C3 test is developed under a license agreement between Nordic Bioscience and Roche Diagnostics. For more information including scientific information on PRO-C3 see https://www.nordicbioscience.com/technology/biomarkers/pro-c3-nordicpro-c3
About Nordic Bioscience
Nordic Bioscience is a Danish biomarker company headquartered in Herlev, Denmark. We are engaged in biomarker development using our unique neoepitope technology. We combine our expertise in biomarker development with preclinical and clinical research. This enables us to develop biomarkers that provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting. For more information about Nordic Bioscience, visit us at https://www.nordicbioscience.com
For product related inquires please use https://www.nordicbioscience.com/contact
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Nordic Bioscience announces PRO-C3 launched by Roche Diagnostics on cobas analysers
|
DUBAI, UAE, Jan. 2, 2026 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, is pleased to announce its New Year Edition Daily Treasure Hunt, an exclusive six-week rewards program powering traders to build early momentum heading into 2026.
The New Year special edition Bybit Daily Treasure Hunt comes with early registration and an extended timeline tiding users over from December 30, 2025 all the way to February 9, 2026. A series of highlights spans daily trading tasks to earn points, unlimited daily draws, and grand prizes including BTC, and Bybit VIP Trial Passes.
All Paths Lead to Rewards
To start earning points, eligible Bybit users may register for the event and pick a rewards path based on their trading styles and preferences:
- Building Daily Trading Momentum: Traders can earn points through completing daily tasks, starting with trades as small as 10 USDT, with extra rewards for consistency by achieving consecutive trading days.
- Exploring Bybit for More Points: Engaging with Bybit's product ecosystem and platform features for extra points.
- Alpha Quests: Embarking on limited-time alpha missions and complete special missions featuring new Bybit products for accelerated point accumulation.
Throughout a treasure-hunting season full of surprises for Bybit's versatile traders, the points earned will convert to tangible value through various reward mechanisms:
- Unlimited Scratch Cards: 50 points per draw with no daily limits from a pool of 1,000,000 cards
- Hot Token Rewards: Access to a curated New Year prize pool featuring trending tokens
- Elite Rewards: High-value rewards including BTC, VIP Trial Passes, and Hot Token airdrops
Getting a headstart in 2026 stands to be both rewarding and fun for traders at Bybit. The special-edition Daily Treasure Hunt aspires to ring in a winning year for Bybit users as they explore the digital asset class and level up their trading skills.
Terms and conditions apply. For details on eligibility and potential restrictions, users may visit: [New Year Edition] Daily Treasure Hunt: Find your alpha
#Bybit / #CryptoArk / #IMakeIt
About Bybit
Bybit is the world's second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.
For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit's Communities and Social Media
Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube
DUBAI, UAE, Jan. 2, 2026 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, is pleased to announce its New Year Edition Daily Treasure Hunt, an exclusive six-week rewards program powering traders to build early momentum heading into 2026.
The New Year special edition Bybit Daily Treasure Hunt comes with early registration and an extended timeline tiding users over from December 30, 2025 all the way to February 9, 2026. A series of highlights spans daily trading tasks to earn points, unlimited daily draws, and grand prizes including BTC, and Bybit VIP Trial Passes.
All Paths Lead to Rewards
To start earning points, eligible Bybit users may register for the event and pick a rewards path based on their trading styles and preferences:
- Building Daily Trading Momentum: Traders can earn points through completing daily tasks, starting with trades as small as 10 USDT, with extra rewards for consistency by achieving consecutive trading days.
- Exploring Bybit for More Points: Engaging with Bybit's product ecosystem and platform features for extra points.
- Alpha Quests: Embarking on limited-time alpha missions and complete special missions featuring new Bybit products for accelerated point accumulation.
Throughout a treasure-hunting season full of surprises for Bybit's versatile traders, the points earned will convert to tangible value through various reward mechanisms:
- Unlimited Scratch Cards: 50 points per draw with no daily limits from a pool of 1,000,000 cards
- Hot Token Rewards: Access to a curated New Year prize pool featuring trending tokens
- Elite Rewards: High-value rewards including BTC, VIP Trial Passes, and Hot Token airdrops
Getting a headstart in 2026 stands to be both rewarding and fun for traders at Bybit. The special-edition Daily Treasure Hunt aspires to ring in a winning year for Bybit users as they explore the digital asset class and level up their trading skills.
Terms and conditions apply. For details on eligibility and potential restrictions, users may visit: [New Year Edition] Daily Treasure Hunt: Find your alpha
#Bybit / #CryptoArk / #IMakeIt
About Bybit
Bybit is the world's second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.
For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit's Communities and Social Media
Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
New Year Special: Bybit Daily Treasure Hunt Kicks Off 2026 with Six Weeks of Rewards
